









Markets
/
Stocks
/
nasdaq-mrsn
/

Mersana Therapeutics Inc

MRSN

7.250USD

-0.100-1.36%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

1.45MMarket Cap

LossP/E TTM



Mersana Therapeutics Inc

7.250

-0.100-1.36%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

108 / 506

Overall Ranking

211 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

72.857

Target Price

+891.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 52.35% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 40.50M.

Overvalued

The company’s latest PE is -0.03, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.57M shares, decreasing 47.18% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 307.14K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.96.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.77, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 3.06M, representing a year-over-year increase of 33.28%, while its net profit experienced a year-over-year increase of 0.12%.

Score

Industry at a Glance

Previous score

5.77

Change



Financials

6.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.31

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.03, which is 2959.46% below the recent high of -0.91 and -8810.14% above the recent low of -2.64.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 108/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.89, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Mersana Therapeutics Inc is 36.00, with a high of 325.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

72.857

Target Price

+891.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Mersana Therapeutics Inc

MRSN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.12, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 8.15 and the support level at 6.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.12

Change

-0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.299

Neutral

RSI(14)

57.096

Neutral

STOCH(KDJ)(9,3,3)

51.273

Neutral

ATR(14)

0.421

Low Volatility

CCI(14)

8.844

Neutral

Williams %R

42.131

Buy

TRIX(12,20)

0.549

Sell

StochRSI(14)

29.674

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.226

Buy

MA10

7.279

Sell

MA20

7.319

Sell

MA50

5.623

Buy

MA100

2.988

Buy

MA200

1.921

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 71.71%, representing a quarter-over-quarter decrease of 2.04%. The largest institutional shareholder is The Vanguard, holding a total of 307.14K shares, representing 6.15% of shares outstanding, with 0.85% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nextech Invest, Ltd.

12.07M

Bain Capital Life Sciences Investors, LLC

8.66M

The Vanguard Group, Inc.

Star Investors

8.38M

+18.71%

Schonfeld Strategic Advisors LLC

7.61M

+259.22%

AQR Capital Management, LLC

5.14M

+27092.58%

Rock Springs Capital Management LP

3.81M

+11.16%

BlackRock Institutional Trust Company, N.A.

7.44M

-10.43%

SilverArc Capital Management, LLC

3.09M

Acadian Asset Management LLC

2.99M

Renaissance Technologies LLC

Star Investors

839.92K

+38.54%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.96, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.